These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29880274)

  • 1. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
    Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
    Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
    Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
    Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
    Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
    JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
    Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
    Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
    Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
    Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer.
    Joshi SS; Handorf ER; Sienko D; Zibelman M; Uzzo RG; Kutikov A; Horwitz EM; Smaldone MC; Geynisman DM
    Eur Urol Oncol; 2020 Feb; 3(1):104-111. PubMed ID: 31326500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
    Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
    Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
    Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
    Buchler T; Bortlicek Z; Poprach A; Pavlik T; Veskrnova V; Honzirkova M; Zemanova M; Fiala O; Kubackova K; Slaby O; Svoboda M; Vyzula R; Dusek L; Melichar B;
    Eur Urol; 2016 Sep; 70(3):469-75. PubMed ID: 26746623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
    Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.